Clinical Trials Using Docetaxel

Clinical trials are research studies that involve people. The clinical trials on this list are studying Docetaxel. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 103

  • A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

    This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel. No control group has been included.
    Location: 3 locations

  • Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1 / PD-1 Antibody and Platinum-Containing Chemotherapy

    This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and anti-PD-L1 / PD-1 antibody, administered concurrently or sequentially.
    Location: 3 locations

  • Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

    This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.
    Location: 3 locations

  • Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer

    This phase I trial investigates the feasibility and safety of an implantable microdevice for the evaluation of drug response in patients with prostate cancer. Implanting and retrieving a microdevice that releases up to 20 drugs directly within the prostate cancer lesion may help to evaluate the effectiveness of several approved cancer drugs against prostate cancer. Once optimized, the implantable microdevice may be able to predict the efficacy of specific drugs for each patient’s tumor and inform therapeutic decision-making.
    Location: 2 locations

  • Combination Chemotherapy and Atezolizumab for the Treatment of Stage IB-IIIA Non-small Cell Lung Cancer

    This phase II trial estimates how many patients with stage IB-IIIA non-small cell lung cancer have measurable circulating tumor deoxyribonucleic acid (ctDNA) in their blood at baseline and unmeasurable ctDNA after receiving 1 year of chemotherapy and atezolizumab. ctDNA is genetic material in the bloodstream that comes from the tumor and is a possible marker of lung cancer returning. Chemotherapy drugs, such as cisplatin, pemetrexed, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding atezolizumab to combination chemotherapy may help kill any remaining cancer cells in patients with non-small cell lung cancer.
    Location: 4 locations

  • Ceritinib and Docetaxel in Treating Patients with Stage IIIB / IV ALK-Negative and EGFR Wild-Type Non-small Cell Lung Cancer

    This phase I trial studies the best dose and side effects of ceritinib and docetaxel in treating patients with stage IIIB / IV ALK-negative and EGFR wild-type non-small cell lung cancer. Ceritinib and docetaxel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ceritinib and docetaxel may work better in treating patients with non-small cell lung cancer.
    Location: 2 locations

  • Combination Chemotherapy and Radiation Therapy in Treating Patients with Locally Advanced HPV Positive Oropharynx Cancer

    This phase II trial studies how well combination chemotherapy followed by reduced dose chemoradiation therapy works in curing patients with locally advanced human papillomavirus (HPV) positive oropharynx cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving combination chemotherapy prior to chemoradiation therapy may result in be less early and late toxicity and side effects then standard chemoradiotherapy in HPV positive oropharynx cancer as there will be fewer side effects.
    Location: 2 locations

  • Neoadjuvant Treatment of Triple Negative Breast Cancer Patients with Docetaxel and Carboplatin to Assess Anti-tumor Activity

    This phase II trial studies how well docetaxel and carboplatin before surgery works in treating patients with stage II-III triple-negative breast cancer that has not previously been treated. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving docetaxel and carboplatin before surgery may help increase the number of patients with no evidence of cancer left after their treatment.
    Location: 2 locations

  • Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

    Background: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with androgen deprivation therapy can improve survival for men with mCSPC. Researchers want to see if combining this treatment with other drugs can help delay the time it takes for mCSPC and mCRPC to get worse. Objective: To learn if giving docetaxel with M7824 and M9241 is safe and effective for men with prostate cancer. Eligibility: Men age 18 and older with mCSPC or mCRPC. Design: Participants will be screened with a medical history and physical exam. Their diagnosis will be confirmed. Their symptoms and how well they do their normal activities will be reviewed. They will have blood and urine tests. Their heart will be evaluated. They will have imaging scans of the chest, abdomen, and pelvis. They will have bone scans with intravenous (IV) injections of Tc99 to check for tumor spread in the bones. Some screening tests will be repeated during the study. Participants may have tumor biopsies. Participants will get treatment in cycles. Each cycle will last 21 days. They will get docetaxel and M7824 through IV infusion. They will get M9241 as an injection under the skin. Participants with mCSPC will have up to 6 cycles. Those with mCRPC will be treated until they cannot tolerate the side effects or their disease gets worse. Participants will have a follow-up visit 30 days after treatment ends. Those with mCSPC will then have follow-up visits at the clinic every 3 months....
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

    The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal adenocarcinoma. NBTXR3 is a drug that when activated by radiation therapy, may cause targeted destruction of cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as oxaliplatin, fluorouracil, capecitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NBTXR3 activated by radiation therapy with concurrent chemotherapy may help control the disease.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

    This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC / GEJC) (MATTERHORN).
    Location: 2 locations

  • Intraperitoneal Docetaxel in Combination with mFOLFOX6 for the Treatment of Gastric Cancer Patients with Peritoneal Carcinomatosis

    This phase I trial evaluates the side effects and best dose of intraperitoneal docetaxel when given together with intravenous combination chemotherapy (mFOLFOX6) in treating patients with gastric cancer that has spread to the peritoneal (abdominal) surface (peritoneal carcinomatosis). Docetaxel works by inhibiting DNA, RNA, and protein creation thus preventing the growth of tumor cells. mFOLFOX6 is a combination of oxaliplatin, leucovorin, and fluorouracil that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) kills more tumor cells. Giving docetaxel directly into the abdomen (intraperitoneal) may result in more of the drug reaching the tumor cells. Giving intraperitoneal docetaxel and intravenous mFOLFOX6 chemotherapy may be effective in treating gastric cancer patients with peritoneal carcinomatosis.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Retifanlimab with Gemcitabine and Docetaxel in Patients with Advanced Soft Tissue Sarcoma

    This phase I / II trial evaluates the effect of gemcitabine and docetaxel when given together with retifanlimab in treating patients with soft tissue sarcoma that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (advanced or metastatic) and cannot be removed by surgery (unresectable). Gemcitabine and docetaxel are chemotherapy drugs that work by killing tumor cells and interrupting their ability to divide and reproduce. Retifanlimab is an antibody, similar to the antibodies made by the immune system to protect the body from harm. Retifanlimab blocks the protein PD-1 (programmed cell death receptor 1), which usually acts as a brake on the immune system. Blocking this protein is like releasing the brakes, so the immune system can target tumor cells and destroy them. Giving gemcitabine and docetaxel together with retifanlimab may shrink or stabilize the cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer

    This is a Phase III, global, multicenter, open-label randomized controlled trial in patients with metastatic or locally advanced unresectable urothelial cancer who have progressed after prior therapy with platinum-based regimen and anti-programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) therapy. Approximately 600 subjects from 123 global sites will be enrolled
    Location: 2 locations

  • Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

    This phase I trial investigates how well pembrolizumab and chemoradiotherapy works in treating patients with gastroesophageal cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as fluorouracil, oxaliplatin and docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Giving pembrolizumab together with chemoradiotherapy may help to control gastroesophageal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Gemcitabine and Docetaxel for the Treatment of Patients with Bladder Cancer

    This phase II trial studies the effect of gemcitabine and docetaxel given directly into the bladder in treating patients with non-muscle invasive bladder cancer patients who have had no prior treatment with bacillus Calmette-Guerin (BCG) (BCG-naive), the current standard of care. Chemotherapy drugs, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

    This Phase II study will recruit 40 metastatic non-small cell lung cancer patients who failed treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, administered simultaneously or sequentially. All recruited patients will receive AB-16B5 at a dose of 12 mg / kg once weekly combined with docetaxel at a dose of 75 mg / m2 once every 3 weeks.
    Location: M D Anderson Cancer Center, Houston, Texas

  • gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study

    This phase I trial uses genotyping to help determine the best dose of irinotecan when given together with fluorouracil, leucovorin, oxaliplatin, and Taxotere (gFOLFOXIRITAX) in treating patients with upper gastrointestinal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Chemotherapy drugs, such as irinotecan, fluorouracil, leucovorin, oxaliplatin, and Taxotere, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1 / PD-L1 Blockade Therapy

    This phase II trial studies how well docetaxel, ramucirumab, and pembrolizumab works for the treatment of non-small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent) in patients who have progressed on platinum-doublet and PD-1 / PD-L1 blockade therapy. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ramucirumab may block new blood vessel growth to reduce tumor growth. Immunotherapy with pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving docetaxel, ramucirumab, and pembrolizumab may work better in shrinking lung cancer.
    Location: 2 locations

  • CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

    This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
    Location: 5 locations

  • Gemcitabine and Docetaxel with Radiation Therapy before Surgery for the Treatment of High Grade and Greater than 5 cm Soft Tissue Sarcoma of the Extremities

    This phase I trial investigates the side effects and best dose of gemcitabine and docetaxel when given together with radiation therapy, and to see how well the combination works before surgery in treating patients with high grade soft tissue sarcoma of the upper or lower limbs (extremities) that is over 5 cm in size. Chemotherapy drugs, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving gemcitabine, docetaxel, and radiation therapy to patients with soft tissue sarcoma of the extremities may lead to a reduction in the size of the tumor prior to surgery. It may also lead to better surgical outcomes and / or reduce the risk of the tumor spreading to other parts of the body.
    Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina

  • Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients with Stage II-III Laryngeal Cancer

    This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cisplatin, docetaxel, and pembrolizumab may help to control the disease.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Androgen Deprivation Therapy (Leuprolide and Degarelix) and Chemoimmunotherapy (Cemiplimab and Docetaxel) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

    This phase II trial studies the side effects of androgen deprivation therapy (leuprolide and degarelix) and chemoimmunotherapy (cemiplimab and docetaxel) and to see how well they work in treating patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic). Testosterone can cause the growth of prostate cancer cells. Leuprolide and degarelix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this study is to determine if the addition of immunotherapy to chemotherapy and androgen deprivation therapy, is safe and improves response to therapy.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

    The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer. Population studied will be female participants experiencing a recurrent platinum-resistant ovarian cancer (no mucinous, low grade serous, or pure sarcoma types), with ≤ 5 prior treatments, and a performance status 0-1.
    Location: 2 locations

  • Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

    The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best administering dose. The study will look at side effects that may happen while taking the combination treatment. A total of approximately 18 subjects will take part in the dose escalation part of the study and an additional 25 subjects will participate in the expansion cohort. This study will be conducted across four centers in the United States.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio